Stem cell therapy: An effective Crohn’s Disease treatment in 2020?

April 7, 2020

Mesenchymal stem cells can target and reduce inflammation in the gastrointestinal tract, even deep within the stomach lining. Stem cell therapy also has a strong immunomodulatory effect, that may have the ability to slow or even stop the progression of the disease.

NEWEST POSTS

Coronavirus (COVID-19) and Multiple Sclerosis - What you should know

Apr 7, 2020

Are people with Multiple Sclerosis more prone to severe Coronavirus related illness? Having a compromised immune system could potentially increase one’s risk of developing severe Coronavirus symptoms. This article aims to answer this question as well as describe the actions MS patients should take to mitigate risk.

Anti-Aging Effects of Mesenchymal Stem Cell Therapy

Apr 7, 2020

Can stem cell therapy cure aging? This article looks at the possible benefits of stem cell therapy in regard to slowing the aging process.

Can stem cells help prevent Coronavirus?

Apr 7, 2020

Reputable laboratory in Golden, Colorado, Vitro Biopharma reports on a potential therapy of Coronavirus (COVID-19) infections by stem cell transplant. While this therapy is not a method to eradicate or cure Coronavirus, there is evidence to support the concept that infected patients may be more likely to combat and survive the infection.

Improvement of bowel function after human umbilical cord mesenchymal stem cell treatment for Crohn’s Disease: A Case Study

Apr 7, 2020

In Crohn's patient, human umbilical cord mesenchymal stem cell implantations led to significant improvement in bowel movements, abdominal discomfort, and blood per rectum. The subject was able to cease steroid medications following treatment and note a sustained increase in quality of life.

My third stem cell treatment for Multiple Sclerosis

Apr 7, 2020

Stem cell therapy results have been extremely positive so far, with approximately 75% of Multiple Sclerosis patients reporting significant improvement within 3 months of treatment, and showing little to no signs of regression out to 18-24 months. Our full Multiple Sclerosis study results are expected to be published later this year.